Full text is available at the source.
Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
Incretin-based treatments for people with obesity and mild or preserved heart pumping function: A review of clinical trials
AI simplified
Abstract
Six randomized clinical trials with 7282 participants indicate that incretin-based therapies may reduce cardiovascular death or worsening heart failure in individuals with obesity-HFpEF.
- Incretin-based therapies reduced the risk of cardiovascular death or worsening heart failure with a hazard ratio of 0.74.
- A reduction in worsening heart failure events was observed with a hazard ratio of 0.62.
- All-cause mortality decreased with incretin-based therapies, indicated by an odds ratio of 0.81.
- Improvements in quality of life and functional status were reported for patients receiving incretin-based therapies.
- Systolic blood pressure and weight were also positively affected in patients with obesity-HFpEF.
AI simplified